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See related research by Tardy-Poncet et al., http://www.ccforum.com/content/19/1/396Heparin-induced thrombocytopenia (HIT) type II is a
highly morbid and potentially life-threatening condition
with limited treatment options in older patients at high
risk of bleeding who develop acute kidney injury (AKI).
The recent study by Tardy-Poncet et al. [1] showing that
argatroban may be a safe and valid therapeutic option in
this patient population is therefore of utmost clinical im-
portance. However, when discussing other alternative
therapies for HIT type II, the authors did not mention
recent experience with fondaparinux, a selective syn-
thetic antithrombin-mediated inhibitor of coagulation
factor Xa [2].
Fondaparinux has often been used off-label to treat HIT
type II in patients without AKI. Maximal treatment effi-
cacy was obtained in all patients at an approximately six-
fold less bleeding risk than in subjects treated with direct
thrombin inhibitors (DTIs), including argatroban [3]. As* Correspondence: Patrick.Honore@az.vub.ac.be
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user-friendly (intermittent subcutaneous injections instead
of continuous infusion) and less expensive. Fondaparinux
is predominantly cleared renally. However, accumulation,
and hence toxicity, is not expected to occur in patients
undergoing renal replacement therapy (RRT). Indeed,
because of its low molecular weight (1.7 kDa) and lack
of binding to proteins other than antithrombin, fonda-
parinux should be eliminated easily by all currently
used intermittent and continuous RRT techniques in
critically ill patients [4]. Moreover, fondaparinux may
form a perfect combination with regional citrate antic-
oagulation to reduce clinical but also dialysis circuit
and filter thrombosis [5]. Of course, appropriate guide-
lines for dose finding, dose modification, and efficacy
monitoring of fondaparinux during RRT must be
elaborated.We read with interest the letter by Honore et al. Even if
our study [1] is the first prospective study, there are nu-
merous retrospective studies that reported the efficacy
of argatroban in the acute phase of HIT in ICU patients
with renal failure and/or hemorrhagic risks. We have
not quoted fondaparinux as a therapeutic option because
the clinical experience of fondaparinux in HIT patients
is still limited despite further previous studies [6–8], es-
pecially in ICU patients.
Questions remain regarding the efficacy, safety, and
optimal doses of fondaparinux (Table 1). The very long
half-life (18 h) of fondaparinux and its accumulation in
the case of renal failure both represent major problemsin critically ill patients, notably in those with hemorrhagic
risk. Indeed, a major bleeding rate of 22 % (six cases
among 27) is observed in HIT patients with a high
hemorrhagic risk, such as those post cardiac surgery with
renal failure (Table 1). Regarding argatroban, continuous
infusion cannot be considered a handicap in ICU patients.
Moreover, its price can be much reduced when the
250 mg/250 ml argatroban vial is fractionated (under a
laminar fluid) in five vials containing 50 mg/50 ml each
that will be used over 5 days.
We do agree that fondaparinux could be used as an
anticoagulant during hemodialysis. However, there are
no convincing data allowing the use of fondaparinux tois distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Heparin-induced thrombocytopenia patients with/without renal failure and treated with fondaparinux after cardiac surgery
Reference N Post cardiac surgery (n) Renal failure (n) HIT-associated thrombosis (n) Major hemorrhage (n) Duration (days) Dose (mg/day)
[6] 15 15 14a 2 2 8–35 1.5–7.5
[7] 11 11 10b 3 3 4–17 2.5–7.5
[8] 16 11 3c 9 1 2–35 2.5–15
HIT Heparin-induced thrombocytopenia
aEleven patients with creatinine clearance <30 ml/min
bEight patients with creatinine clearance <30 ml/min
cOne patient with creatinine clearance <30 ml/min
Honore et al. Critical Care  (2016) 20:14 Page 2 of 2prevent or treat clinical thrombosis in the acute phase of
HIT, especially in ICU patients.
Abbreviations
AKI: Acute kidney injury; DTI: Direct thrombin inhibitor; HIT: Heparin-induced
thrombocytopenia; RRT: Renal replacement therapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PMH and HDS designed the article. PMH, RJ, IH, EDW,VVG, and HDS participated
in drafting the manuscript. All authors read and approved the final version.
References
1. Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel
Y, et al. Argatroban in the management of heparin-induced
thrombocytopenia: a multicenter clinical trial. Crit Care. 2015;19:396.
2. Brown P, Jay R, Fox A, Oliver M. Chronic fondaparinux use in a hemodialysis
patient with heparin-induced thrombocytopenia type II and extracorporeal
circuit thrombosis—a case report and review of the literature. Hemodial Int.
2013;17:444–9.
3. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and
prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother.
2006;40:1383–7.
4. Sharathkumar AA, Crandall C, Lin JJ, Pipe S. Treatment of thrombosis with
fondaparinux (Arixtra) in a patient with end-stage renal disease receiving
hemodialysis therapy. J Pediatr Hematol Oncol. 2007;29:581–4.
5. Kalicki RM, Aregger F, Alberio L, Lammle B, Frey FJ, Uehlinger DE. Use of the
pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
Thromb Haemost. 2007;98:1200–7.
6. Cegarra-Sanmartin V, Gonzales-Rodriguez R, Paniagua-Iglesis P, Santamaria-
Ortiz A, Cueva L, Galan-Serrano J, et al. Fondaparinux as a safe alternative
for managing heparin-induced thrombocytopenia in postoperative cardiac
surgery patients. J Cardiothorac Vasc Anesth. 2014;28:1008–12.
7. Pappalardo F, Scandroglio A, Maj G, Zangrillo A, D’Angelo A. Treatment of
heparin-induced thrombocytopenia after cardiac surgery: preliminary
experience with fondaparinux. J Thorac Cardiovasc Surg. 2010;139:790–2.
8. Warkentin TE, Pai M, Sheppard I, Schulman S, Spyropoulos C. Fondaparinux
treatment of acute heparin-induced thrombocytopenia confirmed by the
serotonine-release assay: a 30-month, 16-patient case series. J Thromb
Haemost. 2011;9:2389–96.
